Jonathan Mc Neill Dyne Therapeutics, Inc. (DYN) insider trading activity

Jonathan Mc Neill is Chief Business Officer of Dyne Therapeutics, Inc.. Currently has a direct ownership of 132,106 shares of DYN, which is worth approximately $2.49 Million. The most recent transaction as insider was on Aug 19, 2024, when has been sold 2,705 shares (Common Stock) at a price of $45.5 per share, resulting in proceeds of $123,077. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 132K

0% 3M change

0% 12M change

Total Value Held $2.49 Million

Jonathan McNeill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 19 2024	SELL Open market or private sale	$123,077 $45.5 p/Share	2,705 Reduced 2.01%	132,106 Common Stock
Jun 11 2024	SELL Open market or private sale	$57,132 $31.34 p/Share	1,823 Reduced 1.33%	134,811 Common Stock
May 16 2024	SELL Open market or private sale	$78,781 $28.4 p/Share	2,774 Reduced 1.99%	136,634 Common Stock
Mar 11 2024	SELL Open market or private sale	$501,589 $25.59 p/Share	19,601 Reduced 12.33%	139,408 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	$98,750 $5.54 p/Share	17,825 Added 10.08%	159,009 Common Stock
Mar 08 2024	SELL Open market or private sale	$2,385,000 $26.5 p/Share	90,000 Reduced 38.93%	141,184 Common Stock
Mar 08 2024	BUY Exercise of conversion of derivative security	$498,600 $5.54 p/Share	90,000 Added 28.02%	231,184 Common Stock

Mar 07 2024	SELL Open market or private sale	$62,918 $25.85 p/Share	2,434 Reduced 1.69%	141,184 Common Stock
Mar 01 2024	SELL Open market or private sale	$703,540 $29.0 p/Share	24,260 Reduced 14.45%	143,618 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$17,709 $0.73 p/Share	24,260 Added 12.63%	167,878 Common Stock
Feb 29 2024	SELL Open market or private sale	$117,370 $27.5 p/Share	4,268 Reduced 2.89%	143,618 Common Stock
Feb 29 2024	BUY Exercise of conversion of derivative security	$3,115 $0.73 p/Share	4,268 Added 2.81%	147,886 Common Stock
Jan 26 2024	SELL Open market or private sale	$496,599 $24.83 p/Share	20,000 Reduced 12.22%	143,618 Common Stock
Jan 26 2024	BUY Exercise of conversion of derivative security	$14,600 $0.73 p/Share	20,000 Added 10.89%	163,618 Common Stock
Jan 04 2024	SELL Open market or private sale	$36,242 $18.04 p/Share	2,009 Reduced 1.38%	143,618 Common Stock
Jan 04 2024	BUY Exercise of conversion of derivative security	$1,466 $0.73 p/Share	2,009 Added 1.36%	145,627 Common Stock
Jan 03 2024	SELL Open market or private sale	$336,251 $18.69 p/Share	17,991 Reduced 11.13%	143,618 Common Stock
Jan 03 2024	BUY Exercise of conversion of derivative security	$13,133 $0.73 p/Share	17,991 Added 10.02%	161,609 Common Stock
Jan 02 2024	SELL Open market or private sale	$155,890 $13.1 p/Share	11,900 Reduced 7.65%	143,618 Common Stock
Dec 11 2023	SELL Open market or private sale	$13,346 $10.72 p/Share	1,245 Reduced 0.79%	155,518 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	-	96,158 Added 38.02%	156,763 Common Stock
Sep 18 2023	SELL Open market or private sale	$11,866 $9.41 p/Share	1,261 Reduced 2.04%	60,605 Common Stock
Sep 12 2023	SELL Open market or private sale	$13,179 $10.41 p/Share	1,266 Reduced 2.01%	61,866 Common Stock
Jun 13 2023	SELL Open market or private sale	$15,649 $12.43 p/Share	1,259 Reduced 1.96%	63,132 Common Stock
Jun 12 2023	SELL Open market or private sale	$13,000 $13.0 p/Share	1,000 Reduced 1.53%	64,391 Common Stock

Also insider at

GLYC

GLYCOMIMETICS INC Healthcare

President and COO